The instruction for medical use of medicine of L' ЭСФАЛЬ the Trade name L'Esfal Mezhdunarodnoye the unlicensed name Is not present the Dosage form Solution for injections of 50 mg/ml Structure 1 ml of drug contains active agent: phosphatidylsincaline from soybeans of 50 mg excipients: benzyl alcohol, acid dezoksikholiyevy, sodium chloride, sodium hydroxide, Riboflavinum (E 101), water for injections. The description Transparent yellow solution Pharmacotherapeutic group Drugs for treatment of diseases of a liver. The ATX A05BA code the Pharmacological Pharmacokinetics Later properties of intravenous administration of a single dose elimination half-life makes 66 hours. Removal of less than 10% of marked substances happens to excrements, through kidneys and respiratory organs within 5-7 days after introduction of a dose. A pharmacodynamics the Phospholipids which are contained in drug on the chemical structure are similar to endogenous phospholipids, but exceed them on the content of polyunsaturated (essential) fatty acids. These high-energy molecules are built in mainly structures of cellular membranes and increase regeneration of hepatic cells. Phospholipids interfere with the broken lipidic exchange by regulation of metabolism of lipoproteins so that neutral fats and cholesterol turn into the transported forms and that is especially important, it occurs due to increase in capacity of capture of cholesterol lipoproteins of high density and can lead to its oxidation, thus. During removal of phospholipids through biliary tract the litogenny index decreases and there is a bile stabilization. Indications as a part of complex therapy fat dystrophy of a liver (steatosis) acute and chronic hepatitis cirrhosis toxic damage of a liver (alcoholic liver disease, medicinal damage of a liver, toxic hepatitis) a cholestasia and prevention of a recurrence of formation of gallstones the significant changes of functional trials of a liver in gestoses of pregnant women the Route of administration and doses It is necessary to apply only transparent solution. The drug is administered intravenously slowly. It is impossible to administer the drug intramusculary because of possible emergence of local reaction. To adults and children 12 years are more senior: appoint intravenously slowly 5-10 ml a day, and in hard cases – from 10 to 20 ml a day. The most single dose of 10 ml of drug. For cultivation of drug it is recommended to use own blood of the patient in the ratio 1:1. The course of treatment makes from 5 to 10 days with the subsequent transition to oral forms of phosphatidylsincaline. In cases when for cultivation of drug it is impossible to use own blood of the patient, it is necessary to apply the solutions free from electrolytes – 5% or 10% solution of glucose, 5% xylitol solution in the ratio 1:1. Side effects In some cases – at use of the raised doses of drug are possible disturbances from digestive tract (diarrhea) In isolated cases – reactions of hypersensitivity, rash, an itching, urticaria. Contraindications hypersensitivity to any of drug components children's age up to 12 years the lactation period Medicinal interactions Are possible medicinal interactions with anticoagulants, in communication with what it is necessary to adjust an anticoagulant dose. Interaction with other medicines was not studied. Drug is not compatible to solutions of electrolytes. Not to administer the drug together with other medicines in one syringe. Special indications of Caution: solution contains benzyl alcohol 5.02 mg/ml. Only for intravenous use. The drug is administered intravenously slowly. It is impossible to administer the drug intramusculary because of possible emergence of local reaction. Use in pediatrics Drug is appointed for treatment of children 12 years are more senior. Uses during pregnancy or feeding by a breast use Drug with care for treatment of toxicosis of pregnant women. Intravenous L'Esfal solution contains benzyl alcohol since. its penetration into a placenta is possible, drug has to be appointed with care during pregnancy. Features of influence on speed of response at control of motor transport or work with other potentially dangerous mechanisms it is not revealed. Overdose of Messages about overdose was not. The form of release and packing On 5 ml of drug spill vampula from glass of brown color with a ring of a break or a point of a break. On ampoules paste labels - self-bondings. On 5 or 10 ampoules together with the instruction for medical use in the state and Russian languages put in a pack with corrugated tabs from cardboard. Or on 5 ampoules put in blister strip packaging from a film polymeric. On 1 or 2 blister strip packagings with ampoules together with the instruction for medical use in the state and Russian languages place in a pack from cardboard. To Store storage conditions in the place protected from light at a temperature from 2C to 8 C. To store out of children's reach! A period of storage 2 years not to use drug after the expiration date specified on packing. Prescription status According to the prescription PJSC Pharmak Producer, Ukraine, 04080, Kiev, st. of Frunze, 63. The owner of the registration certificate of PJSC Pharmak, Ukraine the Address of the organization accepting in the territory of the Republic of Kazakhstan claims from consumers on quality of products (goods) Republic of Kazakhstan, 050012, Almaty, Amanagelda St. 59 'A' Business center 'Shartas', the 9th floor.
Related Products
